BENLYSTA PRESCRIBING INFORMATION PDF

Benlysta mg solution for injection in pre-filled syringe. 2. available information, dose adjustment is not required in patients with mild, moderate or severe. Learn about BENLYSTA (belimumab), an FDA-approved prescription infusion or self-injectable lupus medication to help treat your Request your FREE Info Kit. Belimumab (Benlysta) is a biologic reference with prescribing information, dosage, medication administration, and possible side effects.

Author: Taukree Akinozil
Country: Niger
Language: English (Spanish)
Genre: Business
Published (Last): 1 October 2012
Pages: 127
PDF File Size: 4.39 Mb
ePub File Size: 5.38 Mb
ISBN: 849-4-51948-851-3
Downloads: 28356
Price: Free* [*Free Regsitration Required]
Uploader: Zulkirn

GSK; July 21, Arthritis Rheum ; Differential bnlysta of BAFF and its receptors in discoid lupus erythematosus patients. Evidence supporting the use of methotrexate and rituximab in MG has been published recently, in addition to conflicting randomized trials that were not successful, evaluating the use of tacrolimus as a steroid sparing agent. On March 8,the U. Furuta S, Jayne D. Only articles reporting controlled or prospective studies of biological disease-modifying anti-rheumatic drugs b-DMARDs modulating B cells in treatment benlystq pSS were selected.

Dobrowolski C, Erkan D. Arthritis Care Res Hoboken ;64 6: Cutaneous Lupus Vashisht and colleagues presented their experience of using belimumab for the management of prwscribing lupus at their center. In a systematic review and meta-analysis, Letaief and colleagues examined the clinical safety and effectiveness of B-cell targeted therapies for pSS.

Belimumab (Benlysta) – Medical Clinical Policy Bulletins | Aetna

The primary efficacy end-point was mean change from baseline in the Quantitative Myasthenia Gravis QMG scale at week 24; safety assessments included the frequency and severity of adverse events AEs and serious AEs.

Individual organ manifestations of SLE in past 28 days Flares Score determined by physicians intention to treat 86 total items assessed. Immunotherapy of systemic sclerosis. Treatment prescriing antiphospholipid syndrome beyond anticoagulation. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Aetna considers belimumab Benlysta medically necessary for the treatment of adults aged 18 years or older with active systemic lupus erythematosus SLE and positive autoantibody test e.

  BROTHER MFC 685CW SCAN TO PDF

Lymphocyte counts, Ig levels, and anti-dsDNA antibody levels were available as part of the clinical trial analyses. Long terminal elimination half-life 8. Tacrolimus was associated but no effect was observed with the proteinuria informatikn in the nephrotic range and secondary effects of the glucocorticoids becoming a real concern.

Salivary flow and Schirmer’s test did not change. Last reviewed July b. In the subgroup The authors concluded that long-term treatment with belimumab may be beneficial in SS; randomized, double-blind, controlled studies in larger populations are encouraged.

The dosage for subcutaneous belimumab is mg once weekly.

Benlysta belimumab is provided as mg and mg powder for injection in 5mL and 20mL vials respectively. Jin and Ding summarized up-to-date pharmacological and clinical data of belimumab in the treatment of rheumatoid arthritis RA. Most novel treatments are being developed for arthritis with specific differences between RA and psoriatic arthritis, as well as for SLE, following the approval of belimumab. Belimumab, together with low-doses of MMF, was effective as induction treatment leading to early achievement of complete renal response in these 2 selected cases of LN.

Clinical trials evaluating mycophenolate mofetil as remission induction therapy, gusperimus, belimumab and complement factor C5a inhibition are also ongoing, and many other potential candidates are being investigated both clinically and experimentally.

The authors concluded that these encouraging results justified future randomized controlled trials of belimumab in a prewcribing target population of bsnlysta patients most likely to benefit from treatment.

Patients, investigators, study coordinators, and sponsors were masked to treatment assignment. The authors concluded that informatiln nephritis is a potentially devastating complication of SLE.

  CONCIENCIA BREVE DE IVAN EGUEZ PDF

Intravenous infusion, for therapy, prophylaxis, or diagnosis specify substance or drug ; initial, up to 1 hour. Murine studies include prescriibing of modulators of B cell function e. Emerging therapeutics for rheumatoid arthritis.

Changes in gene expression were consistent with mechanism of action and bnlysta that clinical response to treatment with belimumab was associated with a significant decrease in pro-fibrotic genes and pathways. The Kruskal-Wallis test, the Wilcoxon test, and the analysis of co-variance were used to analyze the continuous variables, as appropriate.

Belimumab was well-tolerated in the treatment of RA over 24 weeks. A phase I trial in patients with systemic lupus erythematosus.

Belimumab (Benlysta)

Clinical trials prescribinh various phases have indicated that belimumab is beneficial for patients with SLE Furie et al, ; Wallace et al, ; Prescriging et al, ; Navarra et al, Individuals with severe central nervous system CNS lupus seizures, psychosis, organic brain syndrome, cerebrovascular accident, cerebritis or CNS vasculitis requiring therapeutic intervention within 60 days of day 0.

Preclinical and clinical studies suggest that belimumab can reduce autoantibody levels in SLE. These researchers studied 5 patients with significant SLE skin manifestations. Furuta and Jayne noted that the current standard therapy for anti-neutrophil cytoplasm antibody-associated vasculitis AAVhigh-dose glucocorticoid and cyclophosphamide followed by azathioprine, has improved the disease prognosis.

GSK; revised July It significantly increased American College of Rheumatology ACR 20 responses at week 24, especially in patients with high disease activity, positive rheumatoid factor, no anti-tumor necrosis factor TNF treatment experience and those who had failed methotrexate therapy.